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RT, histological grade, tumour size or nodal stage. However, 
patients carrying the LAMP3 rs482912 SNP either 
homozygously (n=323) or heterozygously (n=253) had fewer 
locoregional recurrences than those carrying the reference 
allele (n=50, Hazard Ratio (HR) = 0.389, 95% Confidence 
Interval (CI) = 0.196-0.771, P = .007) (figure). This prognostic 
value was limited to patients treated with breast-conserving 
therapy including RT (HR = 0.265, CI = 0.104-0.674, P = .005), 
which is in line with a role for LAMP3 in radiosensitivity. 
Furthermore, the LAMP3 SNP was only prognostic in grade III 
tumours (HR = 0.270, P = .005), tumours larger than 2 cm (HR 
= 0.357, P = .011), and in patients with involved lymph nodes 
(HR = 0.154, P < .001). 
 
Figure: Breast cancer patients that carry the LAMP3 rs482912 
SNP allele (C) either homozygously or heterozygously have 
better locoregional control (P = .007). 
Conclusions: The LAMP3 rs482912 SNP is associated with 
locoregional control in a cohort of 626 breast cancer 
patients. This is specifically the case after RT as part of 
breast conserving treatment and for patients with more 
advanced or aggressive tumours.  
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Purpose/Objective: The incidence of relapse of locally 
advanced lung cancer after treatment with radio(chemo) 
therapy is still high. The significance of biologic markers such 
as heat shock protein (HSPB1) for predicting recurrence has 
been increasingly emphasized by recent investigations. We 
investigated prospectively the association between single 
nucleotide polymorphisms (SNPs) in the HSPB1 gene and the 
risk of relapse in patients with lung cancer. 
Materials and Methods: The data set consist of 156 lung 
cancer patients with available genomic DNA samples and 
treated with radio(chemo)therapy from January 2013 to 
September 2014. Median age was 63 years-old (range, 37-89) 
and the Karnofsky performance status was ≥70 except for 6 
cases. The most common histology for non-small cell lung 
cancer patients (79%) was squamous cell carcinoma (65%). 
Seventythree percent of patients had Stage III disease, 92.3% 
received platinum-based chemotherapy, and received doses 
between 39 Gy and 70 Gy (median, 63 Gy). We genotyped 
three SNPs of the HSPB1 gene (rs2868370, rs2868371, and 
rs7459185) by the TaqMan assays. Cox proportional hazards 
analysis was performed to calculate the hazard ratio (HR) and 
confidence interval (CI) of each genotype on relapse risk. 
Multivariate analyses were performed using a logistic 
regression model, with a stepwise backward elimination 
procedure. A P value of 0.05 or less was considered 
statistically significant. 
Results: The distribution of the HSPB1 genotype was: 
rs2868370, 65% GG, 32% AG, 3% AA; rs2868371, 77% CC, 18% 
CG, 5% GG; rs7459185, 51% GG, 39% CG, 10% GG).The 
incidence of relapse was 31% (24% locoregional and distant, 
18% only locoregional, and 58% only distant). In univariate 
analysis, CG/GG genotypes of HSPB1 rs2868371 were 
associated with a statistically significantly lower risk of any 
relapse (HR = 0.47; 95% CI, 0.23 to 0.97; p = 0.042) and 
distant recurrence (HR = 0.40; 95% CI, 0.17-0.93; p = 0.033) 
compared with the CC genotype. In addition, AG/AA 
genotypes of HSPB1 rs2868370 were associated with a 
statistically significantly higher risk of distant relapse (HR = 
2.19; 95% CI, 1.11 to 4.35; p = 0.024) compared with the GG 
genotype. In multivariate analysis, only the rs2868370 SNP 
retained significance (HR = 2.47; p = 0.010). 
Conclusions: Our results showed that the AG/GG genotypes 
of HSPB1 rs2868370 gene were associated with a higher risk 
of distant relapse in patients with lung cancer treated with 
radio(chemo)therapy and thus may serve as a reliable 
predictor of recurrence. This response marker may be used 
for guiding therapy intensity or as a selection criteria for a 
clinical trial in an individual patient, which would further the 
goal of individualized therapy.  
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Purpose/Objective: In a former study (1), the hypoxia gene 
expression classifier, developed in head and neck squamous 
cell carcinomas, was applied in 89 patients with loco-regional 
gastroesophageal cancer (GC). Analysis of the 15 genes was 
indicative of hypoxia being more profound in esophagus 
squamous cell carcinomas (ESCC) compared with 
adenocarcinomas of the esophago-gastric junction and the 
stomach (AC), and was a potential prognostic marker in 
patients with ESCC. The purpose of the present study was to 
confirm these results. 
Materials and Methods: The study population consisted of 
152 patients with GC treated with neoadjuvant or definitive 
chemoradiotherapy or perioperative chemotherapy. Based on 
formalin-fixed, paraffin-embedded, diagnostic biopsies, gene 
expression of the 15 hypoxia-induced and pH-independent 
genes was obtained with qPCR. Sufficient amounts of RNA for 
gene analyses were available in 135 patients; ESCC: 89 
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patients (66%), AC: 43 patients (32%) and other carcinomas: 3 
patients (2%). Comparing the cohorts of the original and 
present study, patient characteristics were similar except for 
a significantly lower T- and N-stage in the present cohort.  
Tumor specimens were ranked for each of the 15 genes and 
the final rank was the median of the individual gene ranks. A 
low ranking correlated with a more hypoxic genotype and a 
high ranking with a less hypoxic genotype. In addition, a gene 
clustering analysis was performed. 
Results: Consistent with the original study, an unsupervised 
hierarchical clustering of the 15 genes showed inter-group 
heterogeneity between the ESCC and the AC group, and 
intra-group heterogeneity in the ESCC group. Also consistent 
with the original study, no intra-group variability was 
observed for patients with AC. Hence, the analysis suggested 
that hypoxia was more profound in ESCC.  
In contrast, the previous indication of a prognostic value of 
hypoxia in patients with ESCC was not reproducible when 
dividing patients according to ranking, divided by tertiles and 
grouping upper tertile versus mid plus lower tertile (Overall 
survival: HR: 1.01, P=0.98 (Fig. 1)); Disease-specific survival: 
HR: 1.10, P=0.776). However, in line with the previous study, 
the hypoxic status did not correlate with treatment response 
in the ESCC group (P=1.00). 
 
Conclusions: Gene expression analysis of the hypoxia 
classifier confirmed that ESCC hold more hypoxic tumors and 
display greater heterogeneity compared to AC. However, 
previous indications that the hypoxia classifier might hold 
prognostic significance in ESCC patients could not be 
confirmed. Ongoing work includes in vitro studies of 
esophageal cancer cell lines in order to identify alternative 
hypoxia induced genes and to further explore the prognostic 
value of hypoxia in patients with loco-regional 
gastroesophageal cancer. 
(1) Winther M et al, Acta Oncol 52(7):1327-35, 2013. 
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Purpose/Objective: In a recent Phase II trial for locally 
advanced prostate cancer we used a narrow margin around 
the prostate clinical target volume (CTV) and prioritized 
rectum sparing when escalating the dose to the prostate, 
seminal vesicles and pelvic lymph nodes by hypo-fractionated 
IMRT. In this study we use patient-specific statistical motion 
modelling to measure the impact of this compromise on the 
actual delivered CTV dose and related it to treatment 
outcome. 
Materials and Methods: The analysis included twelve 
patients with high risk locally-advanced prostate cancer 
treated in the hypo-fractionated protocol, delivering in 25 
fractions 67.5 Gy to the prostate with 2 mm margin 
(PTV67.5), 60 Gy to the prostate and seminal vesicles with 5 
mm margin (PTV60) and 50 Gy to the prostate, seminal 
vesicles and lymph nodes with 10 mm margin (PTV50). Intra-
prostatic gold markers were used for daily image-guidance. 
Rectum sparing (<50 Gy to half the circumference and V60 Gy 
of less than 10 ml) was prioritized. All patients had twice 
weekly repeat CT scans in which all CTVs and OARs were 
contoured. The CTs were aligned on the implanted markers 
simulating the actual treatment. For each patient and each 
segmented structure, contour based deformable registration 
was performed to obtain the vector fields between the organ 
geometry samples acquired at different time points. The 
planned dose distribution and the deformation vector fields 
were subsequently used as input for a principal component 
analysis (PCA). The PCA model was used to perform 
treatment course simulations where for each patient, 10 000 
treatment courses of 25 fractions each were simulated. The 
accumulated D98% for the CTVs and accumulated gEUD with 
volume parameter of 8 and 12 for bladder and rectum, 
respectively were compared to outcome after 6 years of 
follow up. 
Results: 
 
 
The planned dose distributions were robust for CTV50 and 
CTV60 with mean expected D98% of 49.8 Gy and 61.9Gy, 
respectively. For CTV67.5, all twelve patients received a 
systematic lower D98% than planned for (differences ranging 
from -0.4 Gy to -4.5 Gy, with average difference of -2.1 Gy) 
(Figure 1). Five out of these experienced recurrences during 
follow up. The CTV67.5 D98% distribution of the patients with 
recurrence had similar expectation values as the patients 
without recurrence (Figure 1). Only three patients 
experienced Gastro Intestinal (GI) adverse effects. A 
tendency towards outcome distributions with higher expected 
gEUD was seen among these patients (Figure 2). No such 
tendency was seen for the bladder.  
Conclusions: We fournd a considerable intra-patient and 
inter-patient spread in the D98% delivered to the CTV67.5 as 
a consequence of tight margins. Patient-specific dosimetric 
treatment course simulations might be a promising tool in 
dose-volume effect analysis. 
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